Sweden combines EU regulatory maturity, national health register depth, Karolinska and Sahlgrenska investigator networks, and strong life sciences infrastructure for data driven clinical research.
Sweden is a high-income Scandinavian nation of approximately 10.5 million people occupying the eastern part of the Scandinavian peninsula, bordering Norway to the west and Finland to the northeast with a long Baltic Sea coastline. An EU member since 1995, Sweden retains the Swedish Krona (SEK) rather than the Euro; a currency consideration for sponsors but not a regulatory barrier. Five cities define the Swedish clinical research geography: Stockholm, the capital and home to Karolinska Institutet, Karolinska University Hospital, and the largest concentration of trial activity; Gothenburg, home of Sahlgrenska University Hospital and AstraZeneca's global R&D operations in Mölndal; Uppsala, site of Sweden's oldest university and a major pharmaceutical research centre; Lund and Malmö in the south, forming the Swedish heart of the cross-border Medicon Valley life sciences cluster; and Umeå in the north, home of the Northern Sweden Population Health Study cohorts and a long tradition of population-based cancer and cardiovascular research. Sweden is a charter member of the European Medicines Agency's scientific committee networks and participates fully in CTIS as an experienced EU member state.
Clinical trials are regulated by Läkemedelsverket; the Swedish Medical Products Agency (MPA); one of Europe's most respected and experienced national competent authorities, with deep involvement in EMA scientific committee work and a regulatory culture known for methodological rigour and transparent dialogue with sponsors. Ethics review is provided by the Swedish Ethical Review Authority (Etikprövningsmyndigheten; EPM), a centralised national body that replaced Sweden's regional ethics committee system in 2019; creating a single, consistent national review standard that is among the most efficient in the EU. Sweden is frequently selected as the Reference Member State for multinational EU CTR submissions, reflecting the international research community's confidence in Swedish regulatory quality. AstraZeneca's global pharmaceutical R&D operations, centred on its Gothenburg/Mölndal campus and deeply integrated with Sahlgrenska University Hospital and the University of Gothenburg, have created an investigator-pharma research ecosystem unique among European academic medical centres; and have anchored Sweden's prominence in respiratory, cardiovascular, and oncology drug development for three decades.
Sweden's population is approximately 77% Swedish-born, with substantial and growing communities from Syria (~2%), Iraq (~1.3%), Poland (~1.2%), Somalia, former Yugoslavia, Iran, and other countries; a multicultural composition that has accelerated since the 2015 refugee influx and creates growing enrollment diversity for sponsors addressing EU and FDA diversity guidance. Educational attainment is among Europe's highest, and English proficiency is exceptional; Swedish investigators conduct clinical research, publish, and communicate with sponsors almost exclusively in English as a matter of routine professional practice, creating a seamlessness in sponsor-site interaction that rivals native English-speaking markets. Median age is approximately 41–42 years; moderately aging but younger than Italy or Austria; providing good depth across a wide range of disease indications without being overly concentrated in geriatric populations. The Swedish healthcare system's universal coverage, comprehensive primary care gatekeeping model, and nationally interoperable electronic health records ensure that every Swedish patient carries a complete and centrally accessible medical history; a structural feature that eliminates the data completeness gaps that affect most global trial populations.
Sweden's disease burden follows the Northern European pattern, with cardiovascular disease the leading cause of death (~35%) and cancer the second (~24%); though Sweden's cancer survival rates are among Europe's highest, reflecting early detection, high-quality treatment access, and comprehensive follow-up through the national Cancer Registry. Prostate cancer has a distinctive Swedish profile: systematic PSA-based screening adoption has created one of the world's most surveillance-dense prostate cancer patient populations, making Sweden the home of landmark prostate cancer natural history studies (the STHLM studies) and a primary destination for prostate cancer drug development. Neurodegenerative disease; particularly Alzheimer's and Parkinson's; is a growing research priority backed by major longitudinal cohort studies. Mental health research has been a Swedish academic strength for decades, supported by psychiatric registers of extraordinary completeness. Respiratory disease, cardiovascular outcomes, and rare genetic disorders each benefit from the population register infrastructure described below.
The personnummer; the structural research advantage that makes Sweden unique in Europe: Every person registered in Sweden is assigned a unique personal identification number (personnummer) that links, across their entire lifetime and across every Swedish healthcare provider, all diagnoses, hospitalisations, prescriptions, cancer registrations, laboratory results, vital status, and socioeconomic data; without gaps, duplications, or dependence on patient-initiated recall. For clinical trial sponsors, this creates something that does not exist in any other European research market: automatic, register-based long-term outcome ascertainment without any patient contact burden. All-cause mortality, cardiovascular events, cancer diagnoses, and hospitalisation endpoints are captured by national registers regardless of whether the patient attends follow-up visits, moves house, or changes physician. The Swedish Cancer Registry has operated on this basis since 1958. The National Patient Register has tracked all inpatient care since 1964, and outpatient specialist care since 1987. The Prescribed Drug Register has captured every prescription filled since 2005. Swedish trial data is, by structural design, more complete and more longitudinally deep than trial data collected anywhere else in Europe.
Sweden's research proposition is unique among European markets because it delivers two distinct advantages simultaneously: the investigator quality and institutional depth of a top-tier academic research ecosystem; Karolinska Institutet, AstraZeneca's research campus, SciLifeLab's genomics infrastructure; and a national data infrastructure that changes the fundamental economics and scientific completeness of long-term outcome trials in ways that no other EU member state can replicate.
Full EU CTR/CTIS integration since 1995 EU accession; Läkemedelsverket (MPA) as one of Europe's most experienced and respected NCAs; centralised national ethics review through EPM replacing the fragmented regional system; Sweden frequently selected as EU Reference Member State for multinational CTIS submissions; Swedish regulatory decisions carry strong scientific standing with EMA scientific committees.
Per-patient costs competitive within the Scandinavian/Nordic tier; register-based outcome ascertainment dramatically reduces long-term follow-up costs; primary endpoints (mortality, cancer, CV events) captured automatically without visit burden; state-funded research infrastructure at Karolinska and SciLifeLab reduces genomics and biomarker costs; total cost-of-data substantially lower than markets requiring active long-term patient follow-up.
Unique personnummer system enabling automatic lifetime health data linkage across all registers; 60+ years of national health register data providing unmatched longitudinal outcome ascertainment; near-zero structural dropout from register follow-up regardless of patient engagement; genetically well-characterised Nordic population plus growing immigrant diversity for enrollment breadth; exceptional patient compliance and protocol adherence rates driven by high health literacy.
Karolinska Institutet; the Nobel Prize in Physiology or Medicine institution; and Karolinska University Hospital as joint research anchor; AstraZeneca global R&D campus in Gothenburg fully integrated with Sahlgrenska University Hospital; SciLifeLab national genomics platform (KTH/KI/SU/UU joint); Genomic Medicine Sweden (GMS) whole-genome sequencing capability; Biobank Sweden with population-scale biosamples; SWEDEHEART; world benchmark cardiac quality registry.
Oncology is Sweden's most internationally prominent research pillar, powered by three interlocking assets: the Swedish Cancer Registry's 60+ years of near-complete national cancer incidence and outcome data; Karolinska Cancer Centre's world-class Phase I–IV investigator depth; and a national clinical genomics infrastructure (Genomic Medicine Sweden) capable of delivering whole-genome sequencing for trial biomarker programs at population scale. Cardiovascular disease is the second major pillar, anchored by SWEDEHEART; the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies; one of the world's most comprehensive cardiac quality registries, which Swedish trial investigators can use to contextualise and verify clinical trial outcome data in ways available nowhere else. Respiratory medicine has extraordinary investigator depth in Gothenburg through the AstraZeneca–Sahlgrenska ecosystem: Swedish investigators have been central to the development of virtually every major AstraZeneca respiratory franchise drug over the past 30 years. Rare diseases benefit disproportionately from the register system; the ability to identify every Swedish patient with a specific rare condition through national register cross-linkage makes Sweden's rare disease enrollment feasibility unmatched in Northern Europe. Pharmacoepidemiology and real-world evidence generation are Swedish specialties that translate directly into clinical trial design advantage: Swedish investigators are among Europe's most experienced in using national register data for trial endpoint validation and comparative effectiveness research.
Stockholm and its immediate region account for the majority of Swedish Phase I–III commercial trial volume, dominated by the dual campuses of Karolinska University Hospital (Solna and Huddinge) and their deep integration with Karolinska Institutet. Gothenburg is the second major hub, with Sahlgrenska University Hospital uniquely positioned adjacent to AstraZeneca's global R&D campus; a proximity that has made it one of Europe's most active sites for respiratory, cardiovascular, and oncology Phase II–III programs. Uppsala's Akademiska Sjukhuset, southern Sweden's Skåne University Hospital across its Lund and Malmö campuses, and the university hospitals in Linköping, Umeå, and Örebro complete a geographically distributed but nationally register-linked site network whose outcomes data depth is consistent regardless of location.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Karolinska University Hospital Solna | Solna | Sweden's flagship academic hospital and the primary clinical campus of Karolinska Institutet; the institution that selects the Nobel Prize in Physiology or Medicine; Phase I–IV across oncology, haematology, neuroscience, cardiology, transplantation, and rare diseases; home of the Karolinska Cancer Centre; the highest-volume Phase I site in Scandinavia and one of Europe's most internationally connected oncology research institutions; directly co-located with KI enabling seamless translational science-to-trial pipeline. |
| 02 | Karolinska University Hospital Huddinge | Stockholm | The southern Stockholm campus of Karolinska University Hospital; Karolinska Institutet affiliate; Phase I–IV with particular strength in haematology, infectious disease, hepatology, gastroenterology, and renal disease; home of the major bone marrow transplantation programme and one of Sweden's leading haematological oncology trial centres; serves the diverse southern Stockholm metropolitan population with a distinct patient demographic profile from the Solna campus. |
| 03 | Sahlgrenska University Hospital | Gothenburg | Sweden's largest hospital by volume and the anchor clinical institution for the Sahlgrenska Academy (University of Gothenburg Faculty of Medicine); Phase I–IV across oncology, cardiovascular, respiratory, neurology, and transplantation medicine; unique in Europe for its direct proximity to AstraZeneca's global R&D campus in adjacent Mölndal; a relationship that has made Sahlgrenska one of the world's most experienced sites for respiratory and cardiovascular Phase II–III trials; SWEDEHEART registry host institution for the western Sweden catchment. |
| 04 | Uppsala University Hospital (Akademiska Sjukhuset) | Uppsala | Sweden's oldest university hospital and the primary clinical base of Uppsala University Faculty of Medicine (founded 1477); Phase I–IV across oncology, haematology, endocrinology, cardiovascular, and rare diseases; historically central to Swedish pharmaceutical research; Uppsala University's Department of Pharmaceutical Biosciences has shaped global pharmacokinetics and pharmacodynamics methodology; strong register-based pharmacoepidemiology research programme; active in EORTC and international haematology cooperative groups. |
| 05 | Skåne University Hospital; Lund | Lund | The Lund campus of southern Sweden's premier university hospital complex; Lund University Faculty of Medicine affiliate and the Swedish heart of the Medicon Valley life sciences cluster; Phase I–IV with particular strength in haematology (one of Europe's foremost bone marrow transplant and haematological malignancy centres), oncology, cardiovascular, and clinical pharmacology; active in major European cooperative oncology and haematology group programs; proximity to Copenhagen and the Danish Medicon Valley institutions enables cross-border research collaboration. |
| 06 | Skåne University Hospital; Malmö | Malmö | The Malmö campus of Skåne University Hospital; Lund University affiliate; Phase II–IV with particular strength in internal medicine, cardiology, metabolic disease, and clinical pharmacology; home of the Malmö Diet and Cancer Study; one of Sweden's major population cohort studies with detailed dietary, biological, and lifestyle data on 30,000+ participants available for biomarker sub-studies; serves the diverse Malmö metropolitan population providing ethnic enrollment diversity atypical for Swedish sites. |
| 07 | Linköping University Hospital | Linköping | Central Sweden's university hospital and the primary clinical institution of Linköping University Faculty of Medicine; Phase II–IV across cardiovascular, oncology, and internal medicine; nationally recognized for cardiac surgery and interventional cardiology research; home of the Swedish Cardiac Surgery Register providing exceptional procedural outcome data; important regional node in the national trial network providing south-central Swedish patient enrollment access with full register linkage. |
| 08 | Norrlands Universitetssjukhus (NUS) | Umeå | Northern Sweden's university hospital and the clinical base of Umeå University Faculty of Medicine; Phase II–IV across oncology, cardiovascular, and internal medicine; institutional home of the Northern Sweden Population Health Study; a major biobank cohort with samples and longitudinal health data from ~120,000 participants, enabling exceptional biomarker sub-study capability for northern Swedish patient populations; unique access to genetically distinct northern Swedish patient cohorts of value for population genetics and pharmacogenomics research. |
| 09 | Örebro University Hospital | Örebro | Central Sweden's major regional university hospital; Örebro University Faculty of Medicine affiliate; Phase II–IV across oncology, cardiovascular, and infectious disease; nationally recognised for gastroenterology research and clinical microbiology; home of Sweden's primary national reference laboratory for clinical microbiology; relevant for sponsors in infectious disease and anti-infective indication development; growing commercial trial portfolio reflecting investment in the Örebro life sciences cluster. |
| 10 | Danderyds Sjukhus | Danderyd | A major Stockholm region hospital with an active Phase II–IV research portfolio; Karolinska Institutet affiliate and one of the most research-active non-university hospitals in Sweden; strong in cardiovascular and emergency medicine research; home of the well-known DALI (Danderyd Cardiovascular Disease Lifestyle Investigation) cohort studies; important complement to the Karolinska campuses for sponsors seeking additional Stockholm metropolitan enrollment capacity in cardiovascular and internal medicine indications. |
| 11 | Södersjukhuset | Stockholm | Southern Stockholm's major hospital and one of Sweden's highest-volume emergency medicine institutions; Karolinska Institutet affiliate; Phase II–IV across internal medicine, cardiovascular, and oncology; serves a diverse inner-city Stockholm patient population with higher ethnic diversity than the Solna and Danderyd campuses; growing Phase II–III commercial portfolio particularly in cardiovascular outcomes and acute medicine trials leveraging the hospital's very high acute patient throughput. |
| 12 | Centralsjukhuset Karlstad | Karlstad | Värmland region's primary hospital and a Phase II–III research site linked to the REGION Värmland population health registers; cardiovascular, oncology, and internal medicine trial activity; provides western Swedish rural and semi-rural patient population access for sponsors seeking all-Sweden geographic enrollment breadth; full personnummer/national register linkage ensuring the same data completeness for outcomes ascertainment as any Swedish university hospital site regardless of its research-centre status. |
Sweden's flagship academic hospital and the primary clinical campus of Karolinska Institutet; the institution that selects the Nobel Prize in Physiology or Medicine; Phase I–IV across oncology, haematology, neuroscience, cardiology, transplantation, and rare diseases; home of the Karolinska Cancer Centre; the highest-volume Phase I site in Scandinavia and one of Europe's most internationally connected oncology research institutions; directly co-located with KI enabling seamless translational science-to-trial pipeline.
The southern Stockholm campus of Karolinska University Hospital; Karolinska Institutet affiliate; Phase I–IV with particular strength in haematology, infectious disease, hepatology, gastroenterology, and renal disease; home of the major bone marrow transplantation programme and one of Sweden's leading haematological oncology trial centres; serves the diverse southern Stockholm metropolitan population with a distinct patient demographic profile from the Solna campus.
Sweden's largest hospital by volume and the anchor clinical institution for the Sahlgrenska Academy (University of Gothenburg Faculty of Medicine); Phase I–IV across oncology, cardiovascular, respiratory, neurology, and transplantation medicine; unique in Europe for its direct proximity to AstraZeneca's global R&D campus in adjacent Mölndal; a relationship that has made Sahlgrenska one of the world's most experienced sites for respiratory and cardiovascular Phase II–III trials; SWEDEHEART registry host institution for the western Sweden catchment.
Sweden's oldest university hospital and the primary clinical base of Uppsala University Faculty of Medicine (founded 1477); Phase I–IV across oncology, haematology, endocrinology, cardiovascular, and rare diseases; historically central to Swedish pharmaceutical research; Uppsala University's Department of Pharmaceutical Biosciences has shaped global pharmacokinetics and pharmacodynamics methodology; strong register-based pharmacoepidemiology research programme; active in EORTC and international haematology cooperative groups.
The Lund campus of southern Sweden's premier university hospital complex; Lund University Faculty of Medicine affiliate and the Swedish heart of the Medicon Valley life sciences cluster; Phase I–IV with particular strength in haematology (one of Europe's foremost bone marrow transplant and haematological malignancy centres), oncology, cardiovascular, and clinical pharmacology; active in major European cooperative oncology and haematology group programs; proximity to Copenhagen and the Danish Medicon Valley institutions enables cross-border research collaboration.
The Malmö campus of Skåne University Hospital; Lund University affiliate; Phase II–IV with particular strength in internal medicine, cardiology, metabolic disease, and clinical pharmacology; home of the Malmö Diet and Cancer Study; one of Sweden's major population cohort studies with detailed dietary, biological, and lifestyle data on 30,000+ participants available for biomarker sub-studies; serves the diverse Malmö metropolitan population providing ethnic enrollment diversity atypical for Swedish sites.
Central Sweden's university hospital and the primary clinical institution of Linköping University Faculty of Medicine; Phase II–IV across cardiovascular, oncology, and internal medicine; nationally recognized for cardiac surgery and interventional cardiology research; home of the Swedish Cardiac Surgery Register providing exceptional procedural outcome data; important regional node in the national trial network providing south-central Swedish patient enrollment access with full register linkage.
Northern Sweden's university hospital and the clinical base of Umeå University Faculty of Medicine; Phase II–IV across oncology, cardiovascular, and internal medicine; institutional home of the Northern Sweden Population Health Study; a major biobank cohort with samples and longitudinal health data from ~120,000 participants, enabling exceptional biomarker sub-study capability for northern Swedish patient populations; unique access to genetically distinct northern Swedish patient cohorts of value for population genetics and pharmacogenomics research.
Central Sweden's major regional university hospital; Örebro University Faculty of Medicine affiliate; Phase II–IV across oncology, cardiovascular, and infectious disease; nationally recognised for gastroenterology research and clinical microbiology; home of Sweden's primary national reference laboratory for clinical microbiology; relevant for sponsors in infectious disease and anti-infective indication development; growing commercial trial portfolio reflecting investment in the Örebro life sciences cluster.
A major Stockholm region hospital with an active Phase II–IV research portfolio; Karolinska Institutet affiliate and one of the most research-active non-university hospitals in Sweden; strong in cardiovascular and emergency medicine research; home of the well-known DALI (Danderyd Cardiovascular Disease Lifestyle Investigation) cohort studies; important complement to the Karolinska campuses for sponsors seeking additional Stockholm metropolitan enrollment capacity in cardiovascular and internal medicine indications.
Southern Stockholm's major hospital and one of Sweden's highest-volume emergency medicine institutions; Karolinska Institutet affiliate; Phase II–IV across internal medicine, cardiovascular, and oncology; serves a diverse inner-city Stockholm patient population with higher ethnic diversity than the Solna and Danderyd campuses; growing Phase II–III commercial portfolio particularly in cardiovascular outcomes and acute medicine trials leveraging the hospital's very high acute patient throughput.
Värmland region's primary hospital and a Phase II–III research site linked to the REGION Värmland population health registers; cardiovascular, oncology, and internal medicine trial activity; provides western Swedish rural and semi-rural patient population access for sponsors seeking all-Sweden geographic enrollment breadth; full personnummer/national register linkage ensuring the same data completeness for outcomes ascertainment as any Swedish university hospital site regardless of its research-centre status.
These are the primary regulatory, academic, and industry bodies shaping Sweden's clinical research ecosystem.
Sweden's national competent authority for clinical trial regulation and medicinal product oversight; one of Europe's most respected and scientifically rigorous NCAs; active in EMA CHMP and other scientific committee work; responsible for Part I scientific review of Swedish CTIS submissions; known for transparent regulatory dialogue, high-quality scientific feedback, and efficient GCP inspection processes; frequently selected as Reference Member State for multinational EU CTR submissions.
Sweden's centralised national ethics review body, established in 2019 to replace the decentralised regional committee system; provides consistent, national-standard Part II ethics review for all Swedish clinical trial sites under EU CTR; the single-body structure eliminates the variation and fragmentation of multi-committee ethics review systems found in most EU member states, delivering greater consistency and efficiency for sponsors operating across multiple Swedish sites simultaneously.
Sweden's national health data authority and the custodian of the national health registers; including the National Patient Register (since 1964), Prescribed Drug Register (since 2005), Cause of Death Register (since 1961), and Medical Birth Register (since 1973); all register data is maintained through the personnummer system enabling cross-register linkage; sponsors seeking register data access for clinical trial outcome ascertainment, feasibility assessment, or pharmacoepidemiological sub-studies engage with Socialstyrelsen for data application and ethics-approved extraction.
One of the world's leading medical universities and the sole Swedish institution responsible for selecting the Nobel Prize in Physiology or Medicine; consistently ranked in the global top five to ten for medical research impact; affiliated with Karolinska University Hospital and the primary driver of the national investigator pipeline; runs major translational research programs in oncology, neuroscience, and immunology; deep international partnerships with NIH, NCI, major European cancer consortia, and all major global pharmaceutical companies.
Sweden's national platform for molecular biosciences, jointly operated by KTH Royal Institute of Technology, Karolinska Institutet, Stockholm University, and Uppsala University; provides world-class genomics, proteomics, single-cell analysis, and bioimaging infrastructure to the Swedish research community; directly supports clinical research biomarker development and precision medicine programs; a critical enabling resource for sponsors requiring advanced molecular biology infrastructure for Swedish trial biomarker sub-studies.
Sweden's national infrastructure for implementing clinical whole-genome sequencing and precision medicine across all Swedish university hospitals; links genomic data with clinical and register-based health data through the personnummer system; provides the analytical and consent framework for prospective genomic profiling of trial participants and retrospective biobank genomic analysis; enables Sweden to offer genotype-matched trial stratification at a population scale unattainable in most European markets.
Sweden's national biobank coordination platform; most clinical samples taken in Swedish healthcare are automatically stored in regional biobanks under a national consent framework, creating a population-scale biological sample archive linked through the personnummer to all national health registers; enables retrospective biomarker studies, prospective biosample collection for clinical trials, and multi-site biological sample harmonisation at a scale and consent completeness that is operationally unmatched in European biobanking.
Global CRO with major Swedish operations across oncology, cardiovascular, and rare disease programs; Phase I–IV trial management; Läkemedelsverket/CTIS regulatory submission expertise; site monitoring and data management across Karolinska, Sahlgrenska, Uppsala, and Skåne university hospitals; real-world evidence and register data linkage capability leveraging the national personnummer infrastructure for pharmacoepidemiological sub-studies and outcomes validation.
International CRO with Swedish operations managing Phase I–IV oncology, respiratory, and cardiovascular programs; established investigator relationships across Karolinska, Sahlgrenska, and Uppsala university hospital networks; deep MPA regulatory expertise and EPM ethics application capability; specialist early-phase and biomarker-driven trial capability leveraging Karolinska Phase I infrastructure and SciLifeLab molecular biology platforms.
Global CRO with Swedish operations supporting Phase II–IV oncology, cardiovascular, and rare disease programs; MPA regulatory strategy and CTIS Reference Member State submission expertise for sponsors using Sweden as their primary EU CTR entry point; register data linkage support for long-term outcome ascertainment sub-studies; established Karolinska and Sahlgrenska site networks for oncology and cardiovascular indication development programs.
Sweden's government innovation agency, co-funding life sciences research infrastructure, clinical trial capacity development, and digital health programs across Swedish academic and industry partners; a key facilitator for public-private partnership opportunities between international sponsors and Swedish academic medical centres; Vinnova's strategic life sciences investment programs support the genomics, biobank, and data infrastructure that gives Swedish trial sites their unique register-linkage capabilities.
Sweden offers one of Europe's strongest environments for data rich clinical research. Its national register infrastructure, experienced academic sites, EU aligned regulation, and English fluent investigator community make it especially valuable for studies that depend on long term follow up, outcome completeness, and precision patient identification.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.